OUTLOOK: Japanese Pharma Anticipates Varying Fortunes
This article was originally published in PharmAsia News
Japanese pharma companies have begun reporting their annual results for the fiscal year ending Mar. 31, and while the numbers appear to be generally in line with expectations, Takeda will be hard hit by the settlement for Actos. Guidance from other firms for the current year has also raised some analyst eyebrows.